IL7 and leukemia: Using CX-4945, we demonstrated that CK2 pharmacological inhibition impaired JAK/STAT5 and PI3K/Akt signaling pathway activation triggered by IL-7 or by IL7R mutational activation [58] and consequently impaired the pro-leukemia effects of IL-7 [25].